ALLERGY THERAPEUTICS PLC

Board/Management Information • Mar 11, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6640Z

Allergy Therapeutics PLC

11 March 2013

11 March 2013

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of results and shareholder update

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines will announce its interim results for the period ended 31 December 2012 on 25 March 2013.

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will today release its annual report for the year ended 31 December 2012. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 30 September 2012

	£ '000
Total Non Current Assets	14,378
Total Current Assets	16,469
Total Current Liabilities	(11,032)
Total Non Current Liabilities	(5,527)
Total Equity	14,288

Consolidated Income Statement for the 12 months ended 30 September 2012

	£ '000
Revenue	39,808
Profit for the period	11

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2012.

- Ends -

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	+44 (0) 207 776 1200
Juliet Thompson/ Clare Terlouw
FTI Consulting	+44 (0) 207 831 3113
Simon Conway/ Susan Stuart

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving gross sales for the previous financial year of £43.8 million, mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCJMMBTMBIBTAJ